Background: The aim of this study was to investigate the occurrence of subclinical atherosclerosis, evaluated by carotid artery intima-media thickness (CIMT) in subjects with newly diagnosed type 2 diabetes. Methods: ...Background: The aim of this study was to investigate the occurrence of subclinical atherosclerosis, evaluated by carotid artery intima-media thickness (CIMT) in subjects with newly diagnosed type 2 diabetes. Methods: A total of 167 subjects, 50 newly diagnosed type 2 diabetic subjects and 117 non-diabetic subjects were included in the study. Obese and overweight newly diagnosed type 2 diabetic patients were matched for age and BMI with obese and overweight non-diabetic subjects. Only postmenopausal women were selected. The following biomarkers were analyzed: fasting glucose, HbA1c, fasting insulin, fasting proinsulin, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, adiponectin, leptin, hs-CRP, urine albumin/creatinine ratio. 75 g oral glucose tolerance test was performed in all subjects. Ultrasound imaging was used to evaluate IMT of the common carotid artery. Results: CIMT was greater in newly diagnosed type 2 patients compared to non-diabetic subjects. When analyzed by BMI, the difference regarding CIMT between diabetic and non-diabetic subjects was significant only in overweight subjects, in both sexes. In univariate analysis in men with newly diagnosed type 2 diabetes, CIMT was positively correlated with age, SBP, triglycerides, leptin and negatively correlated with HDL-cholesterol and in women CIMT was positively correlated with SBP and leptin. Independent determinants of CIMT in patients with newly diagnosed type 2 diabetes were in men age (β = 0.556, p = 0.0028) and log leptin (β = 0.393, p = 0.049) and in women systolic blood pressure (β = 0.48, p = 0.026). Conclusions: Subclinical atherosclerosis is present in newly diagnosed type 2 diabetic subjects. Body fat accumulation in men and hypertension in postmenopausal women have a primary role in increase carotid intima-media thickness.展开更多
Objective:To investigate the effect of liraglutide combined with basal insulin on blood glucose control, lipid metabolism and oxidative stress in patients with newly diagnosed type 2 diabetes mellitus complicated by o...Objective:To investigate the effect of liraglutide combined with basal insulin on blood glucose control, lipid metabolism and oxidative stress in patients with newly diagnosed type 2 diabetes mellitus complicated by obesity.Methods: A total of 58 patients with newly diagnosed type 2 diabetes mellitus complicated by obesity who were diagnosed and treated in Xi'an No. 4 Hospital between February 2017 and August 2017 were divided into the control group (n=29) who received basal insulin therapy and the liraglutide group (n=29) who received liraglutide combined with basal insulin therapy according to random number table. The differences in the levels of glycolipid metabolism indexes and the contents of oxidative stress indexes were compared between the two groups before and after treatment.Results: Before treatment, the differences in the levels of glycolipid metabolism indexes in peripheral blood and the contents of oxidative stress indexes in serum were not statistically significant between the two groups. After 1 month of treatment, glucose metabolism indexes FBG and HOMA-IR levels in peripheral blood of liraglutide group were lower than those of control group;lipid metabolism indexes TC, TG, ApoB levels in peripheral blood were lower than those of control group, ApoA1 level was higher than those of control group;serum oxidation indexes MDA and LHP contents were lower than those of control group whereas anti-oxidation indexes GSH-Px and T-AOC contents were higher than those of control group.Conclusion: Liraglutide combined with basal insulin therapy can further control the glucolipid metabolism levels and inhibit the systemic oxidative stress response in patients with newly diagnosed type 2 diabetes mellitus complicated by obesity.展开更多
目的观察初诊2型糖尿病患者采用达格列净联合二甲双胍治疗的效果。方法106例初诊2型糖尿病患者,根据随机抽签法分为对照组与观察组,每组53例。对照组采用二甲双胍治疗,观察组采用二甲双胍联合达格列净治疗。比较两组治疗前及治疗后3个...目的观察初诊2型糖尿病患者采用达格列净联合二甲双胍治疗的效果。方法106例初诊2型糖尿病患者,根据随机抽签法分为对照组与观察组,每组53例。对照组采用二甲双胍治疗,观察组采用二甲双胍联合达格列净治疗。比较两组治疗前及治疗后3个月的空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)水平,用药期间不良反应发生情况。结果治疗前,两组患者的FBG、2 h PG、HbA1c比较,差异无统计学意义(P>0.05);治疗后3个月,两组患者的FBG、2 h PG、HbA1c均低于本组治疗前,且观察组患者的FBG(5.16±0.64)mmol/L、2 h PG(7.63±1.02)mmol/L、HbA1c(5.03±0.59)%均低于对照组的(6.73±0.98)mmol/L、(8.84±1.69)mmol/L、(7.34±0.93)%,差异具有统计学意义(P<0.05)。用药期间,观察组不良反应发生率为3.77%(2/53),对照组不良反应发生率为1.89%(1/53)。两组患者用药期间的不良反应发生率比较,差异无统计学意义(P>0.05)。结论临床中在对初诊2型糖尿病患者进行治疗时,二甲双胍与达格列净联合用药,可有效控制患者的血糖水平,用药方案安全可靠,值得推广。展开更多
目的探讨新诊断2型糖尿病(type 2 diabetes mellitus,T2DM)患者酮症起病的危险因素,并构建预测模型。方法回顾性分析2017年1月至2022年6月在温州市人民医院内分泌科住院的新诊断T2DM患者205例,根据是否酮症起病分为单纯起病组(125例)、...目的探讨新诊断2型糖尿病(type 2 diabetes mellitus,T2DM)患者酮症起病的危险因素,并构建预测模型。方法回顾性分析2017年1月至2022年6月在温州市人民医院内分泌科住院的新诊断T2DM患者205例,根据是否酮症起病分为单纯起病组(125例)、酮症起病组(80例),比较两组患者的临床特征,采用Logistics回归分析酮症发生的危险因素,建立预测模型并采用受试者工作特征(receiver operator characteristic,ROC)曲线评价其对新诊断T2DM患者酮症起病的预测价值。结果与单纯起病组相比,酮症起病组患者男性多见(P=0.009)、年龄更小(P<0.001),收缩压(P=0.003)、高密度脂蛋白(high density lipoprotein,HDL)(P=0.001)、空腹及餐后2小时C肽水平(P<0.001)、促甲状腺激素(thyroid-stimulating hormone,TSH)(P=0.003)、血清游离三碘甲状腺原氨酸(free triiodothyronine,FT3)(P=0.012)更低;起病后下降体重(P<0.001)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)(P<0.001)、稳态模型胰岛素抵抗指数(homeostasis model of assessment for insulin resistance index,HOMA-IR)(P<0.001)更高;多因素Logistics回归结果显示,年龄、HDL、空腹C肽水平、TSH是酮症发生的独立保护因素,HbA1c、HOMA-IR是独立危险因素;根据多因素Logistics回归分析结果建立新诊断T2DM患者酮症预测模型,该模型的曲线下面积(area under the curve,AUC)为0.880[95%CI(0.832,0.928),P<0.001],特异度80.8%、灵敏度86.3%,ROC曲线结果显示,酮症预测模型较各独立指标可更好地预测新诊断T2DM患者酮症的发生。结论年龄、HDL、空腹C肽水平、TSH是新诊断T2DM患者酮症发生的独立保护因素,HbA1c、HOMA-IR是独立危险因素,酮症预测模型对酮症倾向的发生有较好的预测作用。展开更多
文摘Background: The aim of this study was to investigate the occurrence of subclinical atherosclerosis, evaluated by carotid artery intima-media thickness (CIMT) in subjects with newly diagnosed type 2 diabetes. Methods: A total of 167 subjects, 50 newly diagnosed type 2 diabetic subjects and 117 non-diabetic subjects were included in the study. Obese and overweight newly diagnosed type 2 diabetic patients were matched for age and BMI with obese and overweight non-diabetic subjects. Only postmenopausal women were selected. The following biomarkers were analyzed: fasting glucose, HbA1c, fasting insulin, fasting proinsulin, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, adiponectin, leptin, hs-CRP, urine albumin/creatinine ratio. 75 g oral glucose tolerance test was performed in all subjects. Ultrasound imaging was used to evaluate IMT of the common carotid artery. Results: CIMT was greater in newly diagnosed type 2 patients compared to non-diabetic subjects. When analyzed by BMI, the difference regarding CIMT between diabetic and non-diabetic subjects was significant only in overweight subjects, in both sexes. In univariate analysis in men with newly diagnosed type 2 diabetes, CIMT was positively correlated with age, SBP, triglycerides, leptin and negatively correlated with HDL-cholesterol and in women CIMT was positively correlated with SBP and leptin. Independent determinants of CIMT in patients with newly diagnosed type 2 diabetes were in men age (β = 0.556, p = 0.0028) and log leptin (β = 0.393, p = 0.049) and in women systolic blood pressure (β = 0.48, p = 0.026). Conclusions: Subclinical atherosclerosis is present in newly diagnosed type 2 diabetic subjects. Body fat accumulation in men and hypertension in postmenopausal women have a primary role in increase carotid intima-media thickness.
文摘Objective:To investigate the effect of liraglutide combined with basal insulin on blood glucose control, lipid metabolism and oxidative stress in patients with newly diagnosed type 2 diabetes mellitus complicated by obesity.Methods: A total of 58 patients with newly diagnosed type 2 diabetes mellitus complicated by obesity who were diagnosed and treated in Xi'an No. 4 Hospital between February 2017 and August 2017 were divided into the control group (n=29) who received basal insulin therapy and the liraglutide group (n=29) who received liraglutide combined with basal insulin therapy according to random number table. The differences in the levels of glycolipid metabolism indexes and the contents of oxidative stress indexes were compared between the two groups before and after treatment.Results: Before treatment, the differences in the levels of glycolipid metabolism indexes in peripheral blood and the contents of oxidative stress indexes in serum were not statistically significant between the two groups. After 1 month of treatment, glucose metabolism indexes FBG and HOMA-IR levels in peripheral blood of liraglutide group were lower than those of control group;lipid metabolism indexes TC, TG, ApoB levels in peripheral blood were lower than those of control group, ApoA1 level was higher than those of control group;serum oxidation indexes MDA and LHP contents were lower than those of control group whereas anti-oxidation indexes GSH-Px and T-AOC contents were higher than those of control group.Conclusion: Liraglutide combined with basal insulin therapy can further control the glucolipid metabolism levels and inhibit the systemic oxidative stress response in patients with newly diagnosed type 2 diabetes mellitus complicated by obesity.
文摘目的观察初诊2型糖尿病患者采用达格列净联合二甲双胍治疗的效果。方法106例初诊2型糖尿病患者,根据随机抽签法分为对照组与观察组,每组53例。对照组采用二甲双胍治疗,观察组采用二甲双胍联合达格列净治疗。比较两组治疗前及治疗后3个月的空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)水平,用药期间不良反应发生情况。结果治疗前,两组患者的FBG、2 h PG、HbA1c比较,差异无统计学意义(P>0.05);治疗后3个月,两组患者的FBG、2 h PG、HbA1c均低于本组治疗前,且观察组患者的FBG(5.16±0.64)mmol/L、2 h PG(7.63±1.02)mmol/L、HbA1c(5.03±0.59)%均低于对照组的(6.73±0.98)mmol/L、(8.84±1.69)mmol/L、(7.34±0.93)%,差异具有统计学意义(P<0.05)。用药期间,观察组不良反应发生率为3.77%(2/53),对照组不良反应发生率为1.89%(1/53)。两组患者用药期间的不良反应发生率比较,差异无统计学意义(P>0.05)。结论临床中在对初诊2型糖尿病患者进行治疗时,二甲双胍与达格列净联合用药,可有效控制患者的血糖水平,用药方案安全可靠,值得推广。
文摘目的探讨新诊断2型糖尿病(type 2 diabetes mellitus,T2DM)患者酮症起病的危险因素,并构建预测模型。方法回顾性分析2017年1月至2022年6月在温州市人民医院内分泌科住院的新诊断T2DM患者205例,根据是否酮症起病分为单纯起病组(125例)、酮症起病组(80例),比较两组患者的临床特征,采用Logistics回归分析酮症发生的危险因素,建立预测模型并采用受试者工作特征(receiver operator characteristic,ROC)曲线评价其对新诊断T2DM患者酮症起病的预测价值。结果与单纯起病组相比,酮症起病组患者男性多见(P=0.009)、年龄更小(P<0.001),收缩压(P=0.003)、高密度脂蛋白(high density lipoprotein,HDL)(P=0.001)、空腹及餐后2小时C肽水平(P<0.001)、促甲状腺激素(thyroid-stimulating hormone,TSH)(P=0.003)、血清游离三碘甲状腺原氨酸(free triiodothyronine,FT3)(P=0.012)更低;起病后下降体重(P<0.001)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)(P<0.001)、稳态模型胰岛素抵抗指数(homeostasis model of assessment for insulin resistance index,HOMA-IR)(P<0.001)更高;多因素Logistics回归结果显示,年龄、HDL、空腹C肽水平、TSH是酮症发生的独立保护因素,HbA1c、HOMA-IR是独立危险因素;根据多因素Logistics回归分析结果建立新诊断T2DM患者酮症预测模型,该模型的曲线下面积(area under the curve,AUC)为0.880[95%CI(0.832,0.928),P<0.001],特异度80.8%、灵敏度86.3%,ROC曲线结果显示,酮症预测模型较各独立指标可更好地预测新诊断T2DM患者酮症的发生。结论年龄、HDL、空腹C肽水平、TSH是新诊断T2DM患者酮症发生的独立保护因素,HbA1c、HOMA-IR是独立危险因素,酮症预测模型对酮症倾向的发生有较好的预测作用。
